SciSparc shares are trading higher after the company announced a new article published by Baraghithy on the results from a recent study on 5-methoxy-2-aminoindane, Clearmind Medicine's psychoactive molecule for combating obesity.
Portfolio Pulse from Benzinga Newsdesk
SciSparc shares are trading higher following the publication of a new article by Baraghithy on the results of a recent study involving Clearmind Medicine's psychoactive molecule, 5-methoxy-2-aminoindane, for combating obesity.
August 06, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc shares are trading higher after a new article by Baraghithy highlighted positive results from a study on Clearmind Medicine's psychoactive molecule for obesity.
The positive study results on Clearmind Medicine's molecule for obesity have likely increased investor confidence in SciSparc's potential, driving the stock price higher.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80